title: A high-dose busulfan-thiotepa combination followed by autologous bone marrow transplantation in childhood recurrent ependymoma. A phase-II study.
abstract: Sixteen children with refractory or relapsed ependymoma were entered in a phase-II study of high-dose chemotherapy followed by autologous bone marrow transplantation (ABMT). The conditioning regimen consisted of busulfan 150 mg/m2/day for 4 days and thiotepa 300 mg/m2/day for the 3 following days. All patients had previously been treated by surgery and conventional chemotherapy. Eight of them had also received irradiation at doses ranging from 45 to 55 Gy at the tumor site. At the time of transplantation, 9 patients were in first relapse, 5 in second relapse and 2 in third relapse or more; all had measurable disease; 15 patients were evaluable for response. No radiologic response > 50% was observed. Stable disease and progressive disease were documented in 10 and 5 cases, respectively. The duration of response to this treatment, which lasted for a median time of 7 months (range: 5-8 months), was only evaluable in 5 patients who did not receive further treatment after ABMT. To date, there are 3 disease-free survivors at 15, 25 and 27 months all of whom were treated with second complete surgical resection and local radiotherapy (55 Gy). Toxicity was severe, mainly digestive and cutaneous, and 1 toxicity-related death occurred. Unlike medulloblastomas, ependymomas do not appear to be sensitive to this combination therapy. New therapeutic approaches are warranted.
authors.affiliation: Department of Pediatric Oncology, Gustave Roussy Institute, Villejuif, France.
authors.forename: J
authors.initials: J
authors.lastname: Grill
authors.forename: C
authors.initials: C
authors.lastname: Kalifa
authors.forename: F
authors.initials: F
authors.lastname: Doz
authors.forename: C
authors.initials: C
authors.lastname: Schoepfer
authors.forename: C
authors.initials: C
authors.lastname: Sainte-Rose
authors.forename: D
authors.initials: D
authors.lastname: Couanet
authors.forename: M J
authors.initials: MJ
authors.lastname: Terrier-Lacombe
authors.forename: D
authors.initials: D
authors.lastname: Valteau-Couanet
authors.forename: O
authors.initials: O
authors.lastname: Hartmann
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D002066:Busulfan / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D004305:Dose-Response Relationship, Drug; D004806:Ependymoma / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D018714:Radiotherapy, Adjuvant; D012086:Reoperation; D013852:Thiotepa / Q000008:administration & dosage
chemical_list: D013852:Thiotepa; D002066:Busulfan